Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06123026 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion

StatusCompleted
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified Show 5 more changesShow less
    • Final enrollment: 15 participants — 8% of the 200 planned
    • Results posted: Oct 15, 2026
    • Trial completed
    • Eligibility criteria expanded, about 12 words
    • Site details revised
  2. Primary completion date: Apr 30, 2024 to Jun 30, 2024v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 2023 to Dec 18, 2023
    • Site details revised
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to compare breast symptoms (lactation, engorgement, etc) of individuals who undergo a procedure for second trimester of pregnancy loss between 16 weeks and 20 weeks gestational age. The participants will be randomly placed in two groups, one with a placebo tablet and one with medication called "cabergoline" which are taken immediately after their procedure. Researchers will compare groups to see if there are any significant differences in breast symptoms.
Trial Details
NCT Number NCT06123026
Lead Sponsor Northwestern University
Conditions
(from sponsor)		 Lactation Suppressed, Second Trimester Abortion
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov